Current approaches to the treatment of atopic dermatitis: a review of the literature

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Atopic dermatitis (AtD) ― one of the most common inflammatory skin diseases often characterized by limited or short-time efficacy of traditional treatment options.

The PubMed and eLibrary databases were searched for full text articles and reviews about novel approaches to the treatment of this skin disorder published between 2015 and 2021.

This review aims to provide an overview of the recent pathogenetic pathways which are considered as main immunologic targets in the development of novel therapeutic strategies and discovering of future opportunities in the treatment of AtD. There are analysed and systematized novel data about systemic medications such as Dupilumab and a number of other monoclonal antibodies and JAK-inhibitors recently implemented in the practice and currently are clinical expertising in the different phases of trials of their efficacy and safety. Novel topical medications are considered separately including JAK-inhibitors, phosphodiesterase 4 inhibitor and aryl hydrocarbon receptor modulator. AtD is a complex disease characterized by different underlying molecular mechanisms/endotypes and phenotypes. This heterogeneity advocates against the traditional “one-size-fits-all” therapeutic approaches still used to manage AtD.

Therapies targeting different cytokine axes and other mechanisms involved in disease pathogenesis will expand our ability of control of AtD including his therapy-refractory cases. Recent research advancements about clinical and immunological disease’s variability and different endotypes indicate that control of this disorder must be based on pathogenetic approaches and therefore on the concept of individualized therapy.

Full Text

Restricted Access

About the authors

Evgenii V. Bakurov

Ural Research Institute for Dermatovenerology and Immunopatology

Author for correspondence.
Email: bakurov.1981@mail.ru
ORCID iD: 0000-0001-7472-7817
SPIN-code: 9412-4733

MD, Cand. Sci. (Med.), Research Associate

Russian Federation, 8, Scerbacova street, Yekaterinburg, 620076

References

  1. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. JEADV. 2018;32(4):657–682. doi: 10.1111/jdv.14891
  2. Montes-Torres A, Llamas-Velasco M, Pérez-Plaza A, et al. Biological treatments in atopic dermatitis. J Clin Med. 2015;4(4):593–613. doi: 10.3390/jcm4040593
  3. Kim JE, Kim JS, Cho DN. Molecular mechanisms of cutaneous inflammatory disorder: atopic dermatitis. Int J Mol Sci. 2016;17(8):1234–1237. doi: 10.3390/ijms17081234
  4. Nakatsuji T, Chen TH, Narala S, et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med. 2017;9(378):eaah4680. doi: 10.1126/scitranslmed.aah4680.
  5. Rerknimitr P, Otsuka A, Nakashima C, Kabashima K. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangment and pruritus. Inflamm Regen. 2017;37:14–16. doi: 10.1186/s41232-017-0044-7
  6. Mortz CG, Andersen KE, Dellgren C, et al. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: Prevalence, persistence and comorbidities. Allergy. 2015;70(8):836–845. doi: 10.1111/all.12619
  7. Sanchez-Borgez M, Capriles-Hulett A, Ortega-Martell JA, Zubeldia IA. New and potential treatments for atopic dermatitis: biologicals and small molecules. Current Allergy and Asthma Reports.2019;19(3):18. doi: 10.1007/s11882-019-0849-3
  8. Brunner PM, Guttman-Yassky Е, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4):65–76. doi: 10.1016/j.jaci.2017.01.011
  9. Gandhi NA, Pirozzi G, Graham NM. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi: 10.1080/1744666X.2017.1298443
  10. Van de Veen W, Akdis M. The use of biologics for immune modulation in allergic diseases. J Clin Invest. 2019;129(4):1452–1462. doi: 10.1016/j.anai.2018.06.026
  11. Bang CH, Song JY, Song YM, et al. Production of IL-31 in CD45RO(+)CLA(+)H4R(+) T Cells in Atopic Dermatitis. J Clin Med. 2021;10(9):1976. doi: 10.3390/jcm10091976
  12. Hamann CR, Thyssen JP. Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis. J Amer Acad Dermatol. 2018;78(3 Suppl 1):37–42. doi: 10.1016/j.jaad.2017.12.018
  13. Noda S, Suárez-Fariñas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136(5):1254–1264. doi: 10.1016/j.jaci.2015.08.015
  14. Topal FA, Zuberbier T, Makris MP, Hofmann M. The role of IL-17, IL-23 and IL-31, IL-33 in allergic skin diseases. Curr Opin Allergy Clin Immunol. 2020;20(4):367–373. doi: 10.1097/ACI.0000000000000658
  15. Klonowska J, Gleń J, Nowicki RJ, Trzeciak M. New cytokines in the pathogenesis of atopic dermatitis-new therapeutic targets. Int J Mol Sci. 2018;19(10):3086. doi: 10.3390/ijms19103086
  16. Adhikary PP, Tan Z, Page BD, Hedtrich S. TSLP as druggable target- a silver-lining for atopic diseases? Pharmacol. Ther. 2021;217:107648. doi: 10.1016/j.pharmthera.2020.107648
  17. Shao Y, Zhang S, Zhang Y, Liu Z. Recent advance of spleen tyrosine kinase in diseases and drugs. Int Immunopharmacol. 2021;90:107168. doi: 10.1016/j.intimp.2020.107168
  18. Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020;16(9):8–5. doi: 10.7573/dic.2020-8-5
  19. Haugh IM, Watson IT, Menter AM. Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib. Proc (Bayl Univ Med Cent). 2018;31(4):524–525. doi: 10.1080/08998280.2018.1480246
  20. Boguniewicz M. Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines. J Allergy Clin Immunol Pract. 2017;6(5):1477–1487. doi: 10.1016/j.jaip.2017.08.031
  21. Paller AS, Siegfried EC, Thaci D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–1293. doi: 10.1016/j.jaad.2020.06.054
  22. Cork MJ, Thaci D, Eichenfield LF, et al. Dupilumab provides favourable long-term safety and efficacy in children aged ≥6 to <12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol. 2021;184(5):857–870. doi: 10.1111/bjd.19460
  23. Melinda J, Gooderham MD, Hong C. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatology. 2018;78(3 Suppl 1):28–36. doi: 10.1016/j.jaad.2017.12.022
  24. Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–172. doi: 10.1016/j.jaci.2018.08.022
  25. Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52. doi: 10.1016/S0140-6736(15)00388-8
  26. Paller AS, Siegfried EC, Simpson EL, et al. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venerol. 2021;35(2):464–475. doi: 10.1111/jdv.16928
  27. Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):21–31. doi: 10.1016/j.anai.2020.08.016
  28. McKeage K, Duggan S. Risankizumab: first global approval. Drugs. 2019;79(8):893–900. doi: 10.1007/s40265-019-01136-7
  29. Samorano LP, Hanifin JM, Simpson EL, Leshem YA. Inadequate response to ustekinumab in atopic dermatitis ― a report of two patients. J Eur Acad Dermatol Venereol. 2016;30(3):522–523. doi: 10.1111/jdv.12918
  30. Wlodek C, Hewitt H, Kennedy CT. Use of ustekinumab for severe refractory atopic dermatitis in a young teenager. Clin Exp Dermatol. 2016; 41(6):625–627. doi: 10.1111/ced.12847
  31. Guttman-Yassky E, Brunner P, Neumann A, Khattri S. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J Am Acad Dermatol. 2018;78(5):872–881. doi: 10.1016/j.jaad.2018.01.016
  32. Ruzicka T, Hanifin JM, Furue M, et al.; XCIMA Study Group. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826–835. doi: 10.1056/NEJMoa1606490
  33. Kabashima K, Furu M, Hanifin J, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142(4):1121–1130. doi: 10.1016/j.jaci.2018.03.018
  34. Imai Y. Interleukin-33 in atopic dermatitis. J Dermatol Sci. 2019;96(1):2–7. doi: 10.1016/j.jdermsci.2019.08.006
  35. Simpson EL, Parnes JR, She D, et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J Am Acad Dermatol. 2019;80(4):1013–1021. doi: 10.1016/j.jaad.2018.11.059
  36. He H, Guttman-Yassky E. JAK Inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181–192. doi: 10.1007/s40257-018-0413-2
  37. Cartron AM, Nguyen TN, Roh YS, et al. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality. Clin Exp Dermatol. 2021;46(5):820–824. doi: 10.1111/ced.14567
  38. Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–1379. doi: 10.1001/jamadermatol.2019.2855
  39. Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913–921. doi: 10.1016/j.jaad.2018.01.018
  40. Guttman-Yassky E, Thaci D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2019;145(3):877–884. doi: 10.1016/j.jaci.2019.11.025
  41. Silverberg JI, Simpson EL, Thyssen JP. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase 3 JADE MONO-2 study. Paper presented at: Revolutionizing Atopic Dermatitis (RAD) Virtual Conference; April 5, Chicago, IL; 2020.
  42. Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255. doi: 10.1111/bjd.18898
  43. Silverberg JI, de Bruin-Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week-52 AD Up study results. J Allergy Clin Immunol. 2021;S0091-6749(21)01212-4. doi: 10.1016/j.jaci.2021.07.036
  44. Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;10290(397):2151–2168. doi: 10.1016/S0140-6736(21)00588-2
  45. Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;10290(397):2169–2181. doi: 10.1016/S0140-6736(21)00589-4
  46. Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047–1055. doi: 10.1001/jamadermatol.2021.3023
  47. Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863–873. doi: 10.1001/jamadermatol.2020.1406
  48. Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;10246(396):255–266. doi: 10.1016/S0140-6736(20)30732-7
  49. Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255. doi: 10.1111/bjd.18898
  50. Pavel AB, Song T, Kim HJ, et al. Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(4):1011–1024. doi: 10.1016/j.jaci.2019.07.013
  51. Ko K, K HJ, Ho PS, et al. Discovery of a novel highly selective histamine h4 receptor antagonist for the treatment of atopic dermatitis. J Med Chem. 2018;61(7):2949–2961. doi: 10.1021/acs.jmedchem.7b01855
  52. Woo TE, Kuzel P. Crisaborole 2% ointment (Eucrisa) for atopic dermatitis. Skin Therapy Lett. 2019;24(2):4–6.
  53. Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of Crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020; 21(2):275–284. doi: 10.1007/s40257-020-00510-6
  54. Kim B, Nasir A, Papp K, et al. A phase 2, randomized, dose-ranging, vehicle- and active-controlled study to evaluate the safety and efficacy of topical ruxolitinib in adult patients with atopic dermatitis. In: Presented at: The 27th European Academy of Dermatology and Venereology (EADV) Congress. Paris; 2018.
  55. Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902–911. doi: 10.1111/bjd.14871
  56. Raoof T, Kircik L, Kuligowski M, et al. 12-Week efficacy and safety data of ruxolitinib cream in adult patients with atopic dermatitis: results from a phase 2 study. In: Presented at: The 24th World Congress of Dermatology (WCD). Milan; 2019.
  57. Nakagawa H, Nemoto O, Igarashi A, et al. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinas inhibitor, in adult patients with atopic dermatitis. J Dermatol. 2020;47(2):114–120. doi: 10.1111/1346-8138.15173
  58. Piscitelli SC, Pavel AB, McHale K, et al. A Phase 1b, rando-mized, single-center trial of topical cerdulatinib (DMVT-502) in patients with mild-to-moderate atopic dermatitis. J Invest Dermatol. 2021;141(7):1847–1851. doi: 10.1016/j.jid.2020.11.031
  59. Vu YH, Hachimoto-Hachiya A, Takemura M, et al. IL-24 negatively regulates keratinocyte differentiation induced by tapinarof, an aryl hydrocarbon receptor modulator: implication in the treatment of atopic dermatitis. Int J Mol Sci. 2020;24(21):9412. doi: 10.3390/ijms21249412
  60. Uppal SK, Chat VS, Kearns DG, Wu JJ. Topical agents currently in phase II or phase III trials for atopic dermatitis. J Drugs Dermatol. 2020;19(10):956–959. doi: 10.36849/JDD.2020.5214

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies